Company Overview and News

0
Transurban: Growing Dividend Opportunity

2018-06-14 seekingalpha
Transurban is in the early stages of an international expansion strategy, and early signs are very promising.
TCL TRAUF

19
Should You Invest in the SPDR S&P Global Infrastructure ETF (GII)?

2018-04-27 zacks
Launched on 01/25/2007, the SPDR S&P Global Infrastructure ETF (GII - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Utilities - Infrastructure segment of the U.S. equity market.
ABFOF SQ FMAT GII SQNXF TCL ABRTY UTX TRAUF

1
ASX down after cautious day of trading

2018-04-12 theage.com.au
Geopolitical tensions have given Australian markets their second consecutive day of losses as investors remained cautious over the threat of missile strikes in Syria.
ASXFF IFGNF TCL ASXFY RFGPF IFN ARLUF ALL RFG TRAUF

1
ASX down after cautious day of trading

2018-04-12 smh.com.au
Geopolitical tensions have given Australian markets their second consecutive day of losses as investors remained cautious over the threat of missile strikes in Syria.
ASXFF IFGNF TCL ASXFY RFGPF IFN ARLUF ALL RFG TRAUF

11
Deals of the day-Mergers and acquisitions

2018-03-23 reuters
March 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Friday:
NPSNY FOX WYNN RBNTF TCL DFILF TRAUF NPSN DFIHY RRETY 0700 FOXA RRHI

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:TCL / TRANSURBAN GROUP on message board site Silicon Investor.

TCLIF - TTC Technology Corp. Techniclone (TCLN)
MAGC:INTERACTIVE NIGHTCLUBS!!CYBARS.COM CTCK CraftClick.com
FirstClass Systems FCS - Computer Based Training on Net u0026+ Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls
STCL - Shared Technologies Cellulat Utah Clay Technology, Inc. UTCL (Small Float)